Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 randomised, double blind, placebo controlled study comparing Acumapimod on top of standard of care (SOC) to placebo plus standard of care in patients undergoing severe exacerbations of COPD

Next Previous
Trial Profile

Phase 3 randomised, double blind, placebo controlled study comparing Acumapimod on top of standard of care (SOC) to placebo plus standard of care in patients undergoing severe exacerbations of COPD

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acumapimod (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 18 Apr 2019 New trial record
  • 15 Apr 2019 According to the Mereo BioPharma media release, company has held a successful Type B end of Phase 2 meeting with the U.S. Food and Drug Administration and will work with the FDA to finalize the pivotal Phase 3 study design.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top